Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

Jun 01, 2017
|
staff reporter

NEW YORK (GenomeWeb) – GenePOC today said that it has received FDA clearance to market its molecular assay for detecting Group B streptococcus and its Revogene molecular diagnostics instrument in the US.

The test and instrument was launched in Europe earlier in the year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. What's Holding Up Home Testing for SARS-CoV-2?

    Premium

  2. FDA Revokes Emergency Use Authorization for Autobio Diagnostics SARS-CoV-2 Serology Test

  3. Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

  4. Cleveland Clinic, Three Other Labs Get FDA EUAs for Coronavirus Tests

  5. DiaSorin Nabs CE Mark for Testosterone Test to Detect Fertility Disorders

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.